Skip to main content
Fig. 4 | Microbiome

Fig. 4

From: The effects of inhaled aztreonam on the cystic fibrosis lung microbiome

Fig. 4

Analysis of shifts in the microbiome of samples collected prior to the initiation of AZLI (excluding those on systemic antibiotics) taken from responders (R) (n = 35) vs non-responders (NR) (n = 28). a Shannon alpha diversity measures comparing samples from R and NR. b PCoA plot showing community-wide differences of samples taken from R vs NR as measured by Bray-Curtis beta diversity measures. PERMANOVA reveals no significant community-wide differences in aggregate (p = 0.49) or when permutations were constrained by patient (p = 0.85). c–f Box plots showing significant differences in the log abundance of organisms at the OTU level present in >20% of samples taken from R vs NR. Wilcoxon rank-sum tests reveal significant differences in organisms belonging to four distinct OTUs

Back to article page